Progressive Pulmonary Fibrosis Slows With Novel Agent

(MedPage Today) -- Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype, the phase III FIBRONEER-ILD...